CC Shareholder Notice: Chemours Sued for Securities Fraud over Alleged Misrepresentations to Investors - Class Action Deadline is December 7
Chemours has been sued for securities fraud after its stock plummeted 18.63% because Chemours allegedly misrepresented the strength of demand for its Opteon products. NEW YORK, Nov. 3, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class...
Covered in this story
Analyst targets on Chemours
- RBC Capital Markets: $13.4 → $14 by Oct 2027 · Sector Perform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $CC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Chemours →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.